Skip to main content
    A

    Atrium Therapeutics, Inc. Common Stock (RNA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $8.34
    +0.02 (+0.24%)

    Market Cap: $148.48M

    Last updated: Nov 06, 2026 at 4:10 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    54%(14/26)
    Avg Surprise
    -11.32%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.63
    Range$-0.67 - $-0.59
    2 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.70+10.0%
    60d ago$-0.67+6.0%
    30d ago$-0.67+6.0%
    7d ago$-0.67+6.0%
    Current$-0.63
    Revenue Consensus
    $12M
    Range$0 - $15M
    5 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-1.54
    Range$-1.80 - $-1.29
    2 analysts
    Revenue Consensus
    $21M
    Range$8M - $25M
    5 analysts
    Last 12 of 26 reported quarters and 2 upcoming estimates
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$-1.54$-1.80 - $-1.29--2--
    Sep 26EST
    		-$-0.63$-0.67 - $-0.59--2
    1
    0
    30d
    		-
    Jun 26
    Reported Aug 13
    		$-1.18$-0.64$-0.64 - $-0.64-84.38%Miss1
    No revisions (30d)
    		+2.5%
    Mar 26
    Reported May 14
    		$-0.97$-1.05$-1.05 - $-1.05+7.62%Beat1
    No revisions (30d)
    		-7.8%
    Dec 25
    Reported Feb 26
    		$-1.59$-1.26$-1.44 - $-0.96-26.19%Miss11
    0
    1
    30d
    		-98.8%
    Sep 25
    Reported Nov 10
    		$-1.27$-1.10$-1.27 - $-0.61-15.45%Miss13
    2
    0
    30d
    		-95.4%
    Jun 25
    Reported Aug 7
    		$-1.21$-0.96$-1.33 - $-0.55-26.04%Miss15
    7
    3
    30d
    		-86.2%
    Mar 25
    Reported May 8
    		$-0.90$-0.88$-1.07 - $-0.55-2.27%Miss11
    0
    1
    30d
    		-13.9%
    Dec 24
    Reported Feb 26
    		$-0.80$-0.78$-0.90 - $-0.57-2.45%Miss9
    5
    4
    30d
    		-1.3%
    Sep 24
    Reported Nov 7
    		$-0.65$-0.72$-0.94 - $-0.46+9.72%Beat10
    1
    0
    30d
    		+8.5%
    Jun 24
    Reported Aug 9
    		$-0.65$-0.78$-0.94 - $-0.60+16.67%Beat8
    No revisions (30d)
    		+1.5%
    Mar 24
    Reported May 9
    		$-0.79$-0.88$-0.95 - $-0.67+10.23%Beat7
    No revisions (30d)
    		-6.8%
    Dec 23
    Reported Feb 28
    		$-0.79$-0.66$-0.88 - $0.07-19.70%Miss6
    No revisions (30d)
    		+10.2%
    Sep 23
    Reported Nov 8
    		$-0.71$-0.75$-0.80 - $-0.73+5.33%Beat5
    No revisions (30d)
    		+13.4%

    Key Metrics

    Valuation
    P/E Ratio-1.66EV/EBITDAN/A
    Price/FCF-0.66xFCF Yield-152.38%
    Profitability
    Profit Margin-184.10%Operating Margin-753.00%
    ROE-44.00%ROIC-44.21%
    Financial Health
    Debt/Equity0.01xInterest CoverageN/A
    Current Ratio8.73xQuick Ratio8.73x
    Trading Statistics
    Beta0.93Avg Volume245.39K
    52-Week High$16.7752-Week Low$7.49

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$8.39
    SMA 20$8.15
    SMA 50$9.25
    SMA 200$19.27
    EMA 10$8.37
    EMA 20$8.37
    EMA 50$9.23
    EMA 200$18.90

    MACD

    Line: -0.13Signal: -0.26Hist: 0.13

    ADX

    ADX: 24.1+DI: 20.9-DI: 22.9

    Aroon & PSAR

    Aroon Up92.0
    Aroon Down44.0
    PSAR$8.02

    Bollinger Bands

    Upper Band$8.80
    Lower Band$7.50
    %B Position1604%(Upper)
    Band Width0.65

    RSI (14-Day)

    Neutral
    46.3

    Momentum Oscillators

    Stoch %K65.4
    Stoch %D78.6
    Williams %R-47.1
    ROC (10d)1.7%
    Momentum0.14
    CCI (20d)58.4
    MFI (14d)68.9

    Volatility Measures

    ATR (14d)$0.41(4.9%)
    StdDev (20d)0.33
    Hist Vol40.6%(High)

    Volume Flow

    VWAP$8.37
    OBV91.9M
    AD Line-7.5M
    CMF (20d)0.078

    Volume Metrics

    Avg Vol (20d)227.0K
    Vol Ratio0.5x(Low)
    VWMA (20d)$8.17

    Pivot Points

    R3$9.04
    R2$8.89
    R1$8.60
    Pivot Point$8.45
    S1$8.16
    S2$8.01
    S3$7.72

    Advanced Oscillators

    TSI-10.03
    Ultimate Osc51.4
    KST-32.83

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$3.00M$19.64M$859,000$12.47M$3.85M$1.57M$2.97M$2.34M$2.04M$3.54M$2.19M$2.82M
    Cost of Revenue$343,000$151,000$1.50MN/A$138.13MN/A$738,000$710,000$687,000$641,000$615,000$47.71M
    Gross Profit$2.66M$19.48M$859,000$12.47M$-134,278,000$1.57M$2.97M$2.34M$1.36M$2.90M$1.58M$-44,896,000
    Operating Expenses$25.28M$36.76M$48.89M$8.46M$36.86M$133.09M$123.96M$100.47M$83.98M$80.09M$68.32M$13.73M
    R&D$15.34M$16.66M$18.50M$154.95M$138.13M$99.49M$95.63M$77.20M$63.94M$66.83M$52.82M$47.71M
    SG&A$10.28M$20.26M$30.40M$5.77M$36.86M$33.60M$28.34M$23.27M$20.73M$13.90M$16.12M$13.73M
    Operating Income$-22,618,000$-17,280,000$-48,035,000$-8,463,000$-171,142,000$-131,517,000$-120,990,000$-98,134,000$-82,626,000$-77,187,000$-66,743,000$-58,625,000
    Interest Income$2.10M$0$0$14.74M$14.48M$16.18M$18.53M$17.97M$11.95M$8.43M$6.41M$6.28M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$391,000$0
    Income Before Tax$-20,186,000$-16,633,000$-48,035,000$-8,463,000$-157,315,000$-115,773,000$-102,257,000$-80,398,000$-70,793,000$-68,855,000$-60,443,000$-52,358,000
    Income Tax Expense$0$0$34,000$-176,000$0$0$0$0$0$597,724$-1$-6,280,000
    Net Income$-20,186,000$-16,633,000$-48,069,000$-8,287,000$-157,315,000$-115,773,000$-102,257,000$-80,398,000$-70,793,000$-68,855,000$-60,443,000$-52,358,000
    EBITDA$-22,275,000$-16,482,000$-47,913,000$-8,394,000$-170,328,000$-130,732,000$-120,252,000$-97,424,000$-81,939,000$-76,546,000$-66,128,000$-58,059,000
    EBIT$-22,618,000$-16,633,000$-48,035,000$-8,463,000$-171,142,000$-131,517,000$-120,990,000$-98,134,000$-82,626,000$-77,187,000$-66,743,000$-58,625,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about RNA

    News

    Atrium Therapeutics, Inc. (RNA) stock price, news, quote and history

    Atrium Therapeutics, Inc. (RNA) focuses on developing RNA therapeutics for cardiomyopathies, with lead candidates ATR 1072 and ATR 1086. The company, incorporated in 2025 and headquartered in San Diego...

    Yahoo Finance Singapore•11/3/26•Neutral

    Form 8K Atrium Therapeutics Inc For: 2 November By Investing.com

    This article from Investing.com announces the filing of a Form 8K by Atrium Therapeutics Inc. for November 2nd. The content is brief, primarily serving as a notice of the regulatory filing.

    Investing.com Nigeria•11/2/26•Neutral

    Form 8K Atrium Therapeutics Inc For: 2 November By Investing.com

    Investing.com reported on an 8K filing from Atrium Therapeutics Inc. for November 2nd. The article itself is very brief, simply stating the fact of the filing and its date...

    Investing.com UK•11/2/26•Neutral

    Atrium Therapeutics to present PRKAG2 nonclinical data at AHA 2026

    Atrium Therapeutics announced it will present nonclinical data for its investigational therapy ATR 1072 at the American Heart Association Scientific Sessions 2026. The data, generated in a mouse model of PRKAG2 syndrome...

    StreetInsider•11/2/26•Bullish

    Atrium Therapeutics to Present Nonclinical Data Showing ATR 1072 Reversed and Improved Features of PRKAG2 Syndrome During HCMS at AHA Scientific Sessions 2026

    Atrium Therapeutics will present new nonclinical data at the AHA Scientific Sessions 2026, demonstrating that its investigational therapy, ATR 1072...

    PR Newswire•11/2/26•Bullish

    RNA Valuation and Fair Value

    P/E
    -1.7x
    P/FCF
    -0.7x
    PEG
    0.0x
    P/B
    0.7x
    See GNG's fair value

    RNA Profitability: Margins, ROIC and FCF

    Gross margin
    98.6%
    Operating margin
    -753.0%
    Net margin
    -184.1%
    ROIC
    -44.2%
    ROE
    -44.0%
    FCF margin
    -604.3%
    FCF yield
    -152.4%

    RNA Competitors

    CompanyTicker
    Mersana Therapeutics IncMRSN
    Sionna Therapeutics, Inc. Common StockSION
    Inovio Pharmaceuticals IncINO
    MaxCyte IncMXCT
    Sutro BiopharmaSTRO
    MacroGenics IncMGNX
    Innate PharmaIPHA
    KORU Medical Systems, Inc.KRMD

    Sector: Healthcare

    RNA Analyst Ratings

    Consensus
    Buy
    Analysts
    4
    Strong Buy
    0
    Buy
    4
    Hold
    0
    Sell
    0
    Strong Sell
    0

    RNA Bull Case vs Bear Case

    Bear case

    • RNA has a -184.1% net profit margin.
    • RNA beat EPS estimates in 25.0% of its last 8 reported quarters.
    • RNA's quarterly revenue changed -21.9% year over year.

    RNA Earnings: Beat Rate and Next Report

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    -17.4%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.63
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    RNA Earnings Date

    RNA reports Nov 12, 2026. The date is confirmed.

    RNA ETF Holders

    GNG tracks 3 ETFs that hold RNA. The largest weights:

    1. iShares Russell 2000 ETF (IWM), 0.16% of the fund
    2. Schwab U.S. Broad Market ETF (SCHB), 0.02% of the fund
    3. Fidelity Enhanced Small Cap Core ETF (FESM), <0.01% of the fund
    Open the ETF Stock Exposure tool for RNA

    See insider activity

    Frequently Asked Questions About RNA

    When does RNA report earnings?

    Atrium Therapeutics, Inc. Common Stock (RNA) is confirmed to report earnings on Nov 12, 2026.

    Does RNA pay dividends?

    Atrium Therapeutics, Inc. Common Stock (RNA) does not currently pay a regular dividend.

    What is RNA's market cap?

    Atrium Therapeutics, Inc. Common Stock (RNA) has a market capitalization of $148.48M with a current stock price of $8.34.

    Related stocks

    Sector: Healthcare

    All stocks starting with R

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In